## Babak Tofighi

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1145948/publications.pdf

Version: 2024-02-01

		516215	552369
45	861	16	26
papers	citations	h-index	g-index
			252
50	50	50	952
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	Scaling opioid overdose prevention and naloxone dispensation among rural and small metro area pharmacists: findings from a qualitative study. Journal of Substance Use, 2023, 28, 568-573.	0.3	1
2	A Telemedicine Buprenorphine Clinic to Serve New York City: Initial Evaluation of the NYC Public Hospital System's Initiative to Expand Treatment Access During the COVID-19 Pandemic. Journal of Addiction Medicine, 2022, 16, e40-e43.	1.4	42
3	Barriers to HIV and Hepatitis C care for people who inject drugs in Colombia. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2022, 34, 633-638.	0.6	4
4	Validation of a tool to assess effectiveness of peer-recruitment for hepatitis C testing and linkage to care among people who inject drugs. Drug and Alcohol Dependence, 2022, 230, 109177.	1.6	1
5	Buprenorphine Telehealth Treatment Initiation and Follow-Up During COVID-19. Journal of General Internal Medicine, 2022, 37, 1331-1333.	1.3	16
6	Perceptions and experiences toward extended-release buprenorphine among persons leaving jail with opioid use disorders before and during COVID-19: an in-depth qualitative study. Addiction Science & Education Science & Educatio	1.2	8
7	A Mixed-Methods Evaluation of the Feasibility of a Medical Management-Based Text Messaging Intervention Combined With Buprenorphine in Primary Care. Substance Abuse: Research and Treatment, 2022, 16, 117822182210782.	0.5	O
8	Outcomes of a NYC Public Hospital System Low-Threshold Tele-Buprenorphine Bridge Clinic at 1 Year. Substance Use and Misuse, 2022, 57, 1337-1340.	0.7	6
9	Internet use and uptake of a web-based prevention and risk reduction intervention for persons who use drugs in New York City – WebHealth4Us study (2013–2016). Substance Abuse, 2022, 43, 1120-1127.	1.1	1
10	Time for Pharmacy Co-dispensing of Naloxone with Prescribed Opioids?. Journal of General Internal Medicine, 2022, , .	1.3	0
11	Association between methadone or buprenorphine use during medically supervised opioid withdrawal and extended-release injectable naltrexone induction failure. Journal of Substance Abuse Treatment, 2021, 124, 108292.	1.5	7
12	E-cigarette use and beliefs among adult smokers with substance use disorders. Addictive Behaviors Reports, 2021, 13, 100329.	1.0	2
13	Comparison of Treatment Retention of Adults With Opioid Addiction Managed With Extended-Release Buprenorphine vs Daily Sublingual Buprenorphine-Naloxone at Time of Release From Jail. JAMA Network Open, 2021, 4, e2123032.	2.8	23
14	Rural and small metro area naloxone-dispensing pharmacists' attitudes, experiences, and support for a frontline public health pharmacy role to increase naloxone uptake in New York State, 2019. Journal of Substance Abuse Treatment, 2021, 129, 108372.	1.5	7
15	Barriers to treatment for opioid use disorder in Colombia. Journal of Substance Use, 2021, 26, 632-638.	0.3	3
16	Early innovations in opioid use disorder treatment and harm reduction during the COVID-19 pandemic: a scoping review. Addiction Science & Eamp; Clinical Practice, 2021, 16, 68.	1.2	46
17	Engagement in the Hepatitis C care continuum among people who use drugs. Journal of Substance Use, 2020, 25, 343-349.	0.3	5
18	Assessing perceptions about medications for opioid use disorder and Naloxone on Twitter. Journal of Addictive Diseases, 2020, 39, 37-45.	0.8	16

#	Article	IF	CITATIONS
19	Detecting illicit opioid content on Twitter. Drug and Alcohol Review, 2020, 39, 205-208.	1.1	9
20	Harmful smartphone applications promoting alcohol and illicit substance use: a review and content analysis in the United States. Translational Behavioral Medicine, 2020, 10, 1233-1242.	1.2	9
21	Expanding treatment for opioid use disorder in publicly funded primary care clinics: Exploratory evaluation of the NYC health + hospitals buprenorphine ECHO program. Journal of Substance Abuse Treatment, 2019, 106, 1-3.	1.5	24
22	Smoking patterns and preferences for technology assisted smoking cessation interventions among adults with opioid and alcohol use disorders. Journal of Substance Use, 2019, 24, 660-665.	0.3	2
23	Perspectives on the HIV continuum of care among adult opioid users in New York City: a qualitative study. Harm Reduction Journal, 2019, 16, 58.	1.3	12
24	Patient Barriers and Facilitators to Medications for Opioid Use Disorder in Primary Care. Substance Use and Misuse, 2019, 54, 2409-2419.	0.7	40
25	Perceptions of extended-release naltrexone, methadone, and buprenorphine treatments following release from jail. Addiction Science & Elinical Practice, 2019, 14, 37.	1.2	36
26	Extended-release vs. oral naltrexone for alcohol dependence treatment in primary care (XON). Contemporary Clinical Trials, 2019, 81, 102-109.	0.8	9
27	Use of Online Opioid Overdose Prevention Training for First-Year Medical Students: A Comparative Analysis of Online versus In-Person Training. Substance Abuse, 2019, 40, 240-246.	1.1	24
28	Technology Use Patterns Among Patients Enrolled in Inpatient Detoxification Treatment. Journal of Addiction Medicine, 2019, 13, 279-286.	1.4	26
29	Smartphone Apps Targeting Alcohol and Illicit Substance Use: Systematic Search in in Commercial App Stores and Critical Content Analysis. JMIR MHealth and UHealth, 2019, 7, e11831.	1.8	78
30	Technology preferences to enhance HIV and HCV care among patients with substance use disorders. Journal of Addictive Diseases, 2018, 37, 157-159.	0.8	4
31	The Role of Technology-Based Interventions for Substance Use Disorders in Primary Care. Medical Clinics of North America, 2018, 102, 715-731.	1.1	54
32	Mobile phone messaging for illicit drug and alcohol dependence: A systematic review of the literature. Drug and Alcohol Review, 2017, 36, 477-491.	1.1	55
33	Buprenorphine prescribing practice trends and attitudes among New York providers. Journal of Substance Abuse Treatment, 2017, 74, 1-6.	1.5	56
34	Text message reminders for improving patient appointment adherence in an office-based buprenorphine program: A feasibility study. American Journal on Addictions, 2017, 26, 581-586.	1.3	14
35	Opioid overdose prevention training with naloxone, an adjunct to basic life support training for first-year medical students. Substance Abuse, 2017, 38, 123-128.	1.1	36
36	Public sector low threshold office-based buprenorphine treatment: outcomes at year 7. Addiction Science & Science & Science & Practice, 2017, 12, 7.	1.2	55

#	Article	IF	CITATIONS
37	Mobile Phone Messaging During Unobserved "Home―Induction to Buprenorphine. Journal of Addiction Medicine, 2016, 10, 309-313.	1.4	9
38	<i>Craigslist</i> as a source for heroin: a report of two cases. Journal of Substance Use, 2016, 21, 543-546.	0.3	10
39	Extended-release naltrexone opioid treatment at jail reentry (XOR). Contemporary Clinical Trials, 2016, 49, 57-64.	0.8	16
40	Text message content preferences to improve buprenorphine maintenance treatment in primary care. Journal of Addictive Diseases, 2016, 35, 92-100.	0.8	20
41	Psychiatric Comorbidity and Substance Use Outcomes in an Office-Based Buprenorphine Program Six Months Following Hurricane Sandy. Substance Use and Misuse, 2015, 50, 1571-1578.	0.7	9
42	Mobile Phone Use Patterns and Preferences in Safety Net Office-Based Buprenorphine Patients. Journal of Addiction Medicine, 2015, 9, 217-221.	1.4	23
43	Outcomes among buprenorphine-naloxone primary care patients after Hurricane Sandy. Addiction Science & Clinical Practice, 2014, 9, 3.	1.2	27
44	Psychiatric Comorbidity, Red Flag Behaviors, and Associated Outcomes among Office-Based Buprenorphine Patients Following Hurricane Sandy. Journal of Urban Health, 2014, 91, 366-375.	1.8	15
45	HIV knowledge and risk behaviors among people who inject heroin in Colombia. Drugs: Education, Prevention and Policy, 0, , 1-7.	0.8	0